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Abstract The human α-globin genes are paralogues,
sharing a high degree of DNA sequence similarity and
producing an identical α-globin chain. Over half of the α-
globin structural variants reported to date are only charac-
terized at the amino acid level. It is likely that a fraction of
these variants, with phenotypes differing from one obser-
vation to another, may be due to the same mutation but on a
different α-globin gene. There have been very few previous
examples of hemoglobin variants that can be found at both
HBA1 and HBA2 genes. Here, we report the results of a
systematic multicenter study in a large multiethnic popula-
tion to identify such variants and to analyze their differ-
ences from a functional and evolutionary perspective. We
identified 14 different Hb variants resulting from identical
mutations on either one of the two human α-globin
paralogue genes. We also showed that the average
percentage of hemoglobin variants due to a HBA2 gene
mutation (α2) is higher than the percentage of hemoglobin
variants due to the same HBA1 gene mutation (α1) and that
the α2/α1 ratio varied between variants. These α-globin
chain variants have most likely occurred via recurrent
mutations, gene conversion events, or both. Based on these
data, we propose a nomenclature for hemoglobin variants
that fall into this category.
Keywords α-Globin genes . Paralogues . Gene conversion .
Hemoglobin variants . Mutations
Introduction
There are close to 1,000 human hemoglobin (Hb) variants
reported to date [1, 2], and new ones are still being
discovered. The vast majority of them are rare, while others,
e.g., Hb S, Hb C, and Hb E, reach high frequencies in
specific population groups [3]. Most Hb variants are
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clinically and hematologically silent, but some cause
hemolytic anemia, e.g., Hb S, some are unstable Hbs,
methemoglobinemia (Hbs M), and some cause cyanosis
(Hb Kansas) or polycythemia due to their increased oxygen
affinity (Hb Ypsilanti, Hb Malmö). There are still other Hb
variants that also lead to thalassemic phenotype (Hb E, Hb
Knossos).
The human α-like globin gene cluster resides on the
telomeric region of chromosome 16. The HBA2 and HBA1
genes are paralogues, i.e., set of homologous genes that have
evolved from gene duplication and can be associated with a
subsequent divergence of function. Both genes have an
almost identical DNA sequence due to sequence homogeni-
zation by a gene conversion event [4]. Each gene yields an
identical 141-amino acid-long α-globin chain, which partic-
ipates with a β-like globin chain to form the Hb tetramers.
From the 332 α-globin chain variants identified to date,
approximately 52% have been only characterized by protein
chemistry methods, which creates uncertainty as to which α-
globin gene is mutated (Table 1). It is likely that a fraction of
these variants may result from the same mutation but on a
different α-globin gene. Identification and comparative study
of these variants would not only provide useful insights into
α-globin gene transcription and translation but can also shed
light into the mechanistic properties of sequence diversifica-
tion of the α-like globin genes. There have been very few
examples of Hb variants that have been previously identified
at both HBA1 and HBA2 genes, namely Hb Frankfurt [5] and
Hb I [6]. Moreover, as the vast majority of Hb variants are
rare, identification and comparative analysis of heterozygous
cases for these variants is problematic, even for laboratories
with large sample volumes.
Here, we report our results from a multicenter study to
identify and comparatively analyze Hb variants that result
from the same mutation but on different α-globin gene
paralogues in a large multiethnic population sample. In
addition, we performed a systematic study in the HbVar
database of Hb variants and thalassemia mutations (http://
globin.bx.psu.edu/hbvar; [1, 3]) to reveal other globin chain
variants that fall into this category. Based on these results,
we propose a nomenclature for related Hb variants.
Materials and methods
Case selection
One hundred and one unrelated individuals, referred to the
Unit of Biochemical Genetics, Henri Mondor Hospital
(Créteil, France), National Haemoglobinopathy Reference
Laboratory, Churchill Hospital, (Oxford, UK), Unit of
Prevention of Thalassemia, Trikala General Hospital (Tri-
kala, Greece), and Department of Pathology and Laboratory
Medicine, Boston University (Boston, USA), were selected
for this study. These subjects were previously identified as
carriers of an Hb variant. Hematological indices were
measured using a Coulter Cell Counter.
Additionally, 64 unrelated cases were identified in HbVar
database of hemoglobin variants and thalassemia mutations
(http://globin.bx.psu.edu/hbvar) and comparatively analyzed
[7, 8]. Finally, additional data were extracted from Online
Mendelian Inheritance in Man, where available (see Tables 2
and 3 for details).
Identification of Hb variants
Each sample was analyzed by cation-exchange high-perfor-
mance liquid chromatography (HPLC) using the Hb Variant I
or II systems with either the 6-min β-Thalassemia short or the
Dual Kit program (BioRad Laboratories, Hercules, CA,
USA). In addition, samples from the National Haemoglobin-
opathy Reference Laboratory were analyzed by isoelectric
focusing, those from Trikala General Hospital were analyzed
by alkaline agarose gel electrophoresis (Hydragel Hemoglo-
bin 7, SEBIA Norcross, GA, USA) and isoelectric focusing,
and samples from Henri Mondor Hospital were characterized
using a battery of electrophoretic and chromatographic tests
(IEF, citrate agar gel electrophoresis, globin chain electropho-
resis at acid and alkaline pH and in the presence of Triton X-
100, CE-HPLC, RP-HPLC), matching perfectly with results
obtained with Hb samples structurally identified as previously
described [9].
DNA was isolated from blood leukocytes, and amplifica-
tion of the HBA2, HBA1, and HBB genes was done using
gene-specific primers [10]. DNA sequence analysis was per-
formed with an automated sequencer (ABI 310, Applied
Biosystems, Foster City, CA, USA, or CEQ 8000, Beckman
Coulter, Fullerton, CA, USA). Detection of α-thalassemia
deletional mutants was carried out by a gap-PCR procedure
[11].
Results
Fourteen different Hb variants, resulting from identical
mutations on either one of the two human α-globin
Table 1 Number of hemoglobin variants due to a mutant human α-
globin gene
Globin genes No. of Hb variantsa
HBA2 95
HBA1 54
HBA2 or HBA1 unknown 173
Found in both HBA2 or HBA1 14
Total 332
a Data from HbVar database (http://globin.bx.psu.edu/hbvar, assessed
in August 2007)
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paralogue genes, were identified during this study. From
these, nine α-globin chain variants were identified in our
study sample, and their hematological and DNA findings
were comparatively analyzed with the same Hb variant
carriers previously published and documented in HbVar,
namely Hb Winnipeg (51 and ten cases, respectively), Hb J-
Meerut (15 and two cases, respectively), Hb Hasharon (12
and three cases, respectively), Hb Lamentin (eight and one
cases, respectively), Hb J-Paris (five and three cases,
respectively), Hb Stanleyville-II (five and 11 cases, respec-
tively), Hb Russ (two and two cases, respectively), Hb
Toulon (two and three cases, respectively), and Hb Hekinan
(one and nine cases, respectively). Also, five more Hb
variants, resulting from identical mutations on either one of
the two human α-globin paralogue genes, were selected
from HbVar database and/or the literature and included in
this study, namely Hb Zurich-Hottingen/Hb Anadour (four
cases), Hb Frankfurt (three cases), Hb Gerland (four cases),
Hb St. Truiden/Hb Jeddah (four cases), and Hb Titusville
(five cases). The hematological indices of the subjects
carrying these α-globin chain variants are provided in
Tables 2 and 3. With the exception of the mildly unstable
Hb Russ and Hb Gerland, the rest of the Hb variants were
stable. Furthermore, all Hb variant were found in chromo-
somes bearing two α-globin genes, except Hb Frankfurt,
where the variant was also found in the context of a −α3.7
thalassemia chromosome [5]. All heterozygous or com-
pound heterozygous (with −α3.7 thalassemia) cases were
asymptomatic or present with a typical α-thalassemia
carrier phenotype, respectively.
Interestingly, however, DNA analysis of the HBA1 and
HBA2 genes revealed that in 23 unrelated Hb variant
carriers, the mutated α-globin gene was different than the
one previously described for each Hb variant. In particular,
we identified Hb Hasharon and Hb Toulon resulting from
an HBA1, instead of a HBA2, gene mutation; Hb Russ and
Hb Winnipeg resulting from a HBA2, instead of a HBA1,
gene mutation; while Hb Stanleyville-II mutation was
found in both the HBA1 or HBA2 genes (Tables 2 and 3).
The mutated gene for Hb Stanleyville-II was previously not
known, as this variant was only characterized at the protein
level [12].
Subsequently, we exploited the large number of unrelat-
ed Hb Winnipeg carriers bearing the c.226G>T mutation in
either the HBA2 or HBA1 gene to address whether the
percentage of the Hb variant can be correlated to the α-
globin gene mutation. Statistical analysis, using SPSS 10
software, showed that Hb Winnipeg carriers cluster in two
distinct groups, determined by the percentage of the Hb
Winnipeg variant. In 38 Hb Winnipeg carriers bearing the
HBA1 gene mutation, Hb Winnipeg percentage varied from
10.3 to 14.2 (13.0±0.7), while in 12 Hb Winnipeg carriers
bearing the HBA2 gene mutation, the percentage of the
variant hemoglobin was between 15.6 and 18.4 (16.9±0.9,
Table 3 Hematological indices and percentage of Hb variants in either the HBA1 or HBA2 genes for heterozygotes with an α-thalassemia
phenotype (−α/αα or −−/αα)
Hb variant Racial/ethnic
background
Samples Hb
(g/dL)
MCV
(fL)
Hb X (%) Hb E
(%)
Number of
α-globin genes
References
ΗΒα1 ΗΒα2
p.N9S (c.29A>G)
Hb Zurich-Hottingen Portuguese 1 16.5 91 – N.M. – −α/αα [24]
p.E27D (c.84G>C)
Hb Hekinan N.A. 1 10.9 83.9 – 23 −α/αα [14]
Hb Hekinan Asian 1 11.3 69 15.8 – 80 −α/αα This report
Hb Hekinan Thai 1 10.2 83 27 – 10 −−/αα [39]
Hb Hekinan Thai 1 8.2 68.6 26.5 – 9.1 −−/αα [39]
Hb Hekinan Burmanese 1 11.2 68 25 – – −−/αα [40]
p.H50Q (c.153C>G)
Hb Frankfurt Portuguese 1 15.2 83 – 36 −α/αα [5]
p.V55A (c.167T>C)
Hb Gerland French 1 12.2 70.6 31 – – −α/αα [29]
Hb Gerland French 1 13 76 31 – – −α/αα [29]
p.D75Y (c.226G>T)
Hb Winnipeg Greek 1 14.2 76.7 – 30.1 – −α/αα This report
p.N78K (c.237C>G)
Hb Stanleyville-II Black 1 11.7 87 28.6 – −α/αα This report
Hb Stanleyville-II Black 1 9.3 89 25.2 – – −α/αα This report
Hb Stanleyville-II Caucasian 1 15.1 80 – 27.4 −α/αα This report
The number of α-globin genes is also provided
N.A. not available, N.M. not measurable
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Fig. 1). The ration of the average percentage of the
abnormal Hb in heterozygotes with HBA2 (α2) and HBA1
mutations (α1) varied from 1.1 to 1.8, with a mean value of
1.3. These results showed that (1) Hb Winnipeg is produced
at a higher rate (approx. 23%) when the underlying
mutation is in the HBA2 gene, and (2) the percentage of
Hb variant could provide initial information regarding the
α-globin gene molecular defect.
We then explored the HbVar database to identify other
Hb variants with similar properties, e.g., identical mutations
in different α-globin genes yielding the same α-globin
chain variant. We identified 64 heterozygous and com-
pound heterozygous, with −α3.7 thalassemia cases, origi-
nating from various ethnic backgrounds (Tables 2 and 3),
creating a total of 14 different Hb variants that fall into this
category. Comparative analysis of all 165 carriers, stratified
on the basis of the Hb variant, showed that the α2/α1
average Hb variant percentage ranged from 0.98 to 1.67.
However, these cases were extremely rare, and therefore,
their comparative analysis does not provide statistical
confidence compared to the Hb Winnipeg cases. Finally,
in three cases, the variant Hb was only characterized by
means of protein sequencing; therefore, the mutated α-
globin gene could not be identified unambiguously, and
these cases were excluded from further analysis.
Discussion
The present study reports the identification and a compara-
tive analysis of the hematological and molecular properties
of Hb variants resulting from the same mutation but residing
on a different α-globin gene. Our effort was facilitated from
the extensive and diverse sample and comprehensive data
recording of large diagnostic centers and reference laborato-
ries participating in this study, most of which are members of
the ITHANET network (http://www.ithanet.eu).
Structural variants have provided important insights intoα-
globin gene transcriptional regulation and translation. In
particular, using in vitro translation experiments, it has been
shown that the HBA2 gene encodes two- to threefold more
protein that the HBA1 gene [13]. However, a more detailed
study of heterozygous cases for an α-globin gene structural
variant showed that the average abnormal Hb percentage in
heterozygotes with HBA2 and HBA1 mutations correspond
to a α2/α1 ratio of 1.19/1, respectively [14]. This ratio,
however, was obtained from the cumulative analysis of all α-
globin chain variants, and the relative position of the variant
amino acid in the α-globin chain or the relative stability of
the variant Hb was not taken into account. The latter may
impact on the final amount of α-globin chain, particularly for
unstable variants, the translational efficiency or the altered
efficiency in hemoglobin tetramer formation. Although the
Hb variant carriers reported herein are phenotypically silent,
this study provides a much safer approach, since the
comparison is more direct and performed between identical
mutations in the α-globin genes, yielding identical globin
chains. To our knowledge, this is the first attempt to
comparatively analyze the mutations in gene paralogues
leading to an identical protein product based on data
collected from such a large multiethnic sample, not only
for the α-globin but also for other gene families.
Our data show that the α2/α1 ratio of the average
percentage of the abnormal Hb in heterozygotes with HBA2
and HBA1 mutations, respectively, varies from 0.98 (Hb J-
Paris-I) to 1.67 (Hb Gerland; Tables 2 and 3). Moreover,
comparison of the α2/α1 ratio of the average percentage of
the abnormal Hbs showed that stable and mildly unstable
abnormal Hbs nicely cluster in two distinct groups with
average α2/α1 ratios of 1.15±0.10 and 1.60±0.09, respec-
tively (Fig. 2). Notably, in all cases summarized in Tables 2
and 3, the percentage of variant Hb has been calculated
using cation-exchange HPLC. Therefore, although these
values come from different centers and published reports,
the use of similar analytical method, apparatus, and analysis
software makes these values virtually comparable. Also, the
large number of Hb Winnipeg cases studied in this context
statistically strengthens the above claims (Table 2). These
data are comparable with previous results from heterozy-
gous cases for 24 different α-globin chain variants [14] but
sharply contradicts with a previous study [13], which
indicated that a mutated HBA2 gene yielding a variant α-
globin chain is expressed at a two- to threefold higher level
than a mutated HBA1 gene. The main supporting data for
this claim were the Hb levels of Hb J-Oxford (40%) and Hb
Hasharon (35%), which are comparable to levels expected
for Hb variant/α-thalassemia compound heterozygotes (see
Fig. 1 Box plots (p<0.001) indicating the range and mean values
(thick black lines) of the Hb Winnipeg variant percentage between
carriers bearing the HBA1 or HBA2 mutation. In our evaluation, the
Hb Winnipeg/α-thalassemia compound heterozygous case, as well as
the cases described in Ref. [32], is excluded
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also Table 3). However, these data were obtained from in
vitro translation experiments, and hence, this discrepancy is
most likely due to the experimental approach rather that
directly measuring Hb variant levels in vivo.
How do these variants occur? Although recurrent muta-
tional events can be a likely cause for some of them,
interallelic gene conversion event is the most plausible cause
that might have resulted in the same mutation being
“transferred” into different genomic contexts. A handful of
examples also exist in the human β-like globin genes
(reviewed in [15]), as well as in other human multigene
families [16]. In favor for this assumption is the fact that 13
out of 14 Hb variants described herein are within exons 1
and 2. These exons, and not exon 3, have been shown to be
involved in gene conversion events, as the 3′ end of the
human α-globin gene conversion tract is located in intron II
(Fig. 3).
Importantly, however, the ethnic background of the family
or the individual where the mutation is found cannot be
always indicative for the likely mechanism that resulted in the
mutation in question. For example, the plethora of Hb
Winnipeg observed in the French population may indicate
recurrent gene conversion events. However, in the cases of Hb
Gerland and Hb Stanleyville-II, although the variants have
been reported in two families from France and Southeast Asia
and in Caucasian and Black families, respectively, recurrent
mutations and (recurrent) gene conversion events are equally
likely mechanisms to have generated the mutations in the
HBA2 and HBA1 genes, and thorough haplotype analysis is
required to favor one mechanism over the other.
Apart from gene conversion events, recurrent unequal
crossovers cannot be completely ruled out as a likely cause
of these Hb variants. Unequal crossovers have been
previously shown to be frequent in the human α-globin
gene family [17, 18]. In particular, two successive unequal
crossover events, i.e., from a normal (αα) to a rearranged
[e.g., deletional (α-) or triplicated (ααα)] chromosome and
back, will be undistinguishable from a gene conversion
event and have the same consequence, e.g., transfer of a
DNA segment from one α-globin gene to another. The
rearranged (intermediate) chromosome bearing the variant
nucleotide can either persist in the population and,
therefore, be found, as in the case of Hb Frankfurt [5] or
can subsequently be lost.
In general, gene conversion events can be identified
from neighboring to the mutation paralogous sequence
Fig. 2 Comparison of the cal-
culated α2/α1 ratio of the aver-
age percentage of the stable (S,
shown in blue bars) and mildly
unstable abnormal Hbs (MU,
shown in red bars) reported in
this paper
Fig. 3 Schematic drawing of the 14 α-globin chain variants resulting
from an identical mutation in either the HBA1 or HBA2 genes.
Original graphs have been automatically generated by HbVar
graphical display [8]. Thick lines under each coding sequence (CDS)
represent the position of each substitution deposited in HbVar. Asterisk
3′ end of the human α-globin gene conversion tract [6], caret PSVs in
the promoter and coding sequences of the human α-globin genes
(c.300+55G/T, c.301-35_29GGCCCTCdel, c.301-24C/G, c.*+15G/A,
c.*+19A/G) deducted from sequence comparison between the HBA2
and HBA1 reference sequences (NG_000006.1; see also Supplemen-
tary data)
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variants (PSVs) that are also transferred along with the
mutation. Therefore, PSVs are valuable, as they provide
insights regarding the length of the gene conversion tract.
The Cretan type of non-deletional hereditary persistence of
fetal hemoglobin stands as a representative example [19,
20]. HBA2 and HBA1 genes have several PSVs outside the
1,436-bp α-globin gene converted region, spanning from
positions −868 to +568 relative to the genes’ transcriptional
initiation site [4], but very few PSVs within this DNA
segment (depicted as “^” in Fig. 3; see also Supplementary
data). Therefore, it is very difficult to unambiguously
distinguish these recombinational events from recurrent
mutations. At present, there is only one well-documented
mutagenic gene conversion event in the human α-globin
gene locus (Hb I; p.K16E) identified in both HBA1 and
HBA2 genes in cis [6]. This resembles Hb F-Charlotte
[HBG1:p.I75T and p.A136E; 21], contrary to Hb F-Way-
nesboro and Hb F-Lesvos [22], which resulted from the
same mutation but in the HBG2 gene (HBG2:p.I75T). Also,
two variant α-globin gene alleles consisting of a small
DNA segment from the other α-globin gene paralogue
(α212 and α121) are most likely the result of a single
crossover between a normal and a recombinant allele,
although a non-reciprocal gene conversion event cannot be
completely ruled out [23]. In all cases, extended haplotype
analysis around these variants is an absolute requirement,
although this is beyond the scope of the present study.
From a formal genetic point of view, despite the fact that
these mutations lead to an identical globin chain, they must
be considered as different mutational events, since the
nucleotide change occurs in another gene. These situations
often cause ambiguities when depositing relevant data in
locus-specific databases, like HbVar [1]. The same situation
is also reported for two mutations leading to α-thalassemia,
namely the c.95+5G>A mutation, found on both α-globin
genes and the c.1A>G (initiation codon mutation), found on
both HBA2 and HBA1 genes and in a hybrid α-globin gene
in the context of α-3.7 thalassemia chromosome. In addition,
apart from the Hb variants reported herein, there are also
Hb variants for which the amino acid change is identical,
but the nucleotide change is different. Such Hb variants are
clearly the products of independent mutational events,
namely Hb G-Philadelphia (p.N68K; HBA2:c.207C>A or
HBA1:c.207C>G), Hb J-Broussais (p.K90N; HBA2:
c.273G>T or HBA1:c.273G>C), and Hb Manitoba (p.
S102R; HBA2:c.307A>C or HBA2:c.309C>A or HBA1:
c.309C>A; also documented as Hb Manitoba I, III, and II,
respectively). Therefore, we propose the use of an appro-
priate suffix in the corresponding variant’s name as a
solution to this issue. We propose the use of the [A1] suffix
for Hb variants due to HBA1 gene and [A2] suffix for
HBA2 gene mutations, e.g., Hb Winnipeg [A1] and Hb
Winnipeg [A2], referring to the HBA1:c.226G>C and
HBA2:c.226G>C mutations, respectively. This proposed
nomenclature is different than the one used for δ-globin
chain variants, e.g., Hb A2-Yialousa, to avoid confusion.
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